Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 59Unknown 11Terminated 8Withdrawn 6Active not recruiting 4Recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms 1Neoplasm, Residual 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Hematologic Diseases 1Esophageal Stenosis 1Esophageal Neoplasms 1Corneal Diseases 1Breast Cancer Patients Treated With T-DXd 1Brain Neoplasms 1Blood Protein Disorders 1Ann Arbor Stage II Mantle Cell Lymphoma 1Amyloidosis 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Dexamethasone × Clear all
NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡